Previous 10 | Next 10 |
Third positive registrational trial met its primary endpoint, with KarXT demonstrating an 8.4-point reduction in PANSS total score compared to placebo at Week 5 (p<0.0001) KarXT was generally well tolerated, with a side effect profile substantially consistent with previous trials of ...
2023-03-13 08:00:00 ET Summary Zai Lab is set to reach several product milestones this year, as at least eight new products are on track for approval by the end of 2025. With $1 billion in cash reserves, the company has sufficient resources to keep exploring new drugs. The vas...
2023-03-06 16:54:50 ET Summary Zai lab's diversified pipeline, strong partnerships, and proven track record of successful drug development make it an attractive investment opportunity in the biotech industry. The recent acceptance of the New Drug Application for sulbactam-durlobac...
Zai Lab Limited (ZLAB) Q4 2022 Earnings Conference Call March 02, 2023 08:00 AM ET Company Participants Billy Cho - Chief Financial Officer Samantha Du - Founder, Chairperson and Chief Executive Officer Josh Smiley - Chief Operating Officer Rafael Amado - President...
The following slide deck was published by Zai Lab Limited in conjunction with their 2022 Q4 earnings call. For further details see: Zai Lab Limited 2022 Q4 - Results - Earnings Call Presentation
Zai Lab press release ( NASDAQ: ZLAB ): FY GAAP EPS of -$4.63 beats by $0.30 . Revenue of $215M (+49.0% Y/Y) misses by $1.4M . As of December 31, 2022, cash and cash equivalents, short-term investments and restricted cash totaled $1,009.3 million, compared to $1,409.9 ...
Total revenue of $215.0 million for 2022, representing a 49.0% increase y-o-y; ZEJULA ® achieved 55.2% y-o-y growth Strong balance sheet with a cash position of $1.0 billion as of December 31, 2022 Company to host conference call and webcast on March 2, 2023, at 8:00 ...
SHANGHAI and CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), today announced that members of the company’s senior management team will participate in the following investor conferences in March 2023: Jefferies 2023 Biotech on the Bay ...
SHANGHAI, China and CAMBRIDGE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) will present two oral presentations highlighting the ad hoc interim overall survival (OS) study results of ZEJULA ® (niraparib) from the NORA Phase 3 study and a post hoc an...
SHANGHAI and CAMBRIDGE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the National Medical Products Administration (NMPA) in China has accepted the New Drug Application (NDA) for sulbactam-durlobactam (SUL-DUR), an investigational drug th...
News, Short Squeeze, Breakout and More Instantly...
First and only NMPA-approved subcutaneous (SC) injectable providing additional flexibility and optionality for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC study Zai Lab Limited (NASDAQ: Z...
Manuscript represents the first publication from China’s gynecology oncology field to be published in Cell Publication highlights first-time learnings about the landscape of ovarian cancer microenvironment stratified by HRD and how a PARP inhibitor perturbs it Data suggest ...
2024-07-05 18:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...